OpenAI on Thursday unveiled a new artificial intelligence model highlighting enhanced capabilities in biology and scientific research, as the company expands further into the life sciences sector.
The model, called GPT-Rosalind and named after 20th-century British scientist Rosalind Franklin, is designed to support research in areas such as biochemistry, drug discovery, and translational medicine.
Read Also – Trump expected to name CDC director nominee today or tomorrow, Kennedy says
Demand for AI-powered tools to speed up drug discovery and research has been growing across pharmaceutical companies, academic institutions, and biotech firms.
“By supporting evidence synthesis, hypothesis generation, experimental planning, and other multi-step research tasks, this model is designed to help researchers accelerate the early stages of discovery,” OpenAI said in a blog.
Researchers using the model will be able to query databases, read the latest scientific papers, use other scientific tools and suggest new experiments, OpenAI said in a press briefing. The model was built on top of OpenAI’s newest internal models.
GPT-Rosalind is available as a research preview in ChatGPT, Codex, and via the API for qualified users through OpenAI’s trusted access framework. The company is also introducing a free Life Sciences research plugin for Codex, which connects scientists to more than 50 scientific tools and data sources.
The company said it is collaborating with customers such as Amgen, Moderna, and Thermo Fisher Scientific to integrate GPT-Rosalind into their workflows.
OpenAI, the creator of ChatGPT, also introduced GPT-5.4-Cyber on Tuesday—a specialized version of its flagship model designed for defensive cybersecurity applications—following rival Anthropic’s announcement of its advanced AI model Mythos.
